Original language | English (US) |
---|---|
Pages (from-to) | 6034-6038 |
Number of pages | 5 |
Journal | Blood Advances |
Volume | 4 |
Issue number | 23 |
DOIs | |
State | Published - Dec 8 2020 |
Funding
This work was supported by a Young Investigator Award from the Conquer Cancer Foundation (S.F.C.), Career Development Program Fellow Awards from the Leukemia & Lymphoma Society (S.F.C. and L.A.M.), a Young Investigator Award from The Truth 365 (S.F.C.), a Momentum Award from the Mark Foundation for Cancer Research (S.F.C.), and an ASH Scholar Award (S.F.C.). This research was also funded in part through a Cancer Center Support grant from the National Institutes of Health National Cancer Institute (P30 CA008748). Conflict-of-interest disclosure: W.X. has received research support from Stemline Therapeutics. S.F.C. has consulted for and holds equity interest in Imago Biosciences. R.L.L. serves on the supervisory board of Qiagen and is a scientific advisor to Loxo, Imago, C4 Therapeutics, and Isoplexis; he receives research support from and has consulted for Celgene and Roche; receives research support from Prelude Therapeutics; has consulted for Novartis and Gilead; and has received honoraria from Lilly and Amgen for invited lectures. L.A.M. has received speaking honoraria from Mission Bio, Inc. M.S.T. receives research funding from Abb-Vie, Cellerant, Orsenix, ADC Therapeutics, Biosight, receives royalties from UpToDate, and serves on the advisory boards of AbbVie, BioLineRx, Daiichi-Sankyo, Orsenix, KAHR, Rigel, Nohla, Delta-Fly Pharma, and Tetraphase. The remaining authors declare no competing financial interests.
ASJC Scopus subject areas
- Hematology